Editpep
June 24, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Brain Health
Editpep is a preclinical therapeutics company spun out of UC Berkeley Innovative Genomics Institute developing a next-generation non-viral delivery platform for in vivo CRISPR medicines. Its proprietary PERC™ technology delivers CRISPR as a transient biologic therapeutic, offering the safety advantages of non-viral, protein-based editing while overcoming the distribution challenges of lipid nanoparticles and unlocking a new class of safer, programmable genomic medicines. Editpep has demonstrated compelling in vivo brain editing in large animal models and is expanding into base editing and additional tissues. The company’s lead program targets Huntington’s disease, with a growing pipeline in CNS and genetic diseases.
Company HQ City:
Berkeley
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2022
CEO
Dana Foss
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}